<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3615">
  <stage>Registered</stage>
  <submitdate>8/08/2012</submitdate>
  <approvaldate>8/08/2012</approvaldate>
  <nctid>NCT01663857</nctid>
  <trial_identification>
    <studytitle>A Study of LY2228820 for Recurrent Ovarian Cancer</studytitle>
    <scientifictitle>A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Study of LY2228820, a p38 MAPK Inhibitor, Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin for Women With Platinum-Sensitive Ovarian Cancer</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>I1D-MC-JIAE</secondaryid>
    <secondaryid>12517</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Epithelial Ovarian Cancer</healthcondition>
    <healthcondition>Fallopian Tube Cancer</healthcondition>
    <healthcondition>Primary Peritoneal Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Ovarian and primary peritoneal</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Womb (Uterine or endometrial cancer)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - LY2228820
Treatment: drugs - Carboplatin
Treatment: drugs - Placebo
Treatment: drugs - Gemcitabine

Experimental: Phase 1b 200 mg LY2228820 - Induction: Cycles 1-6 (21 day cycles)- 200 milligrams (mg) LY2228820 administered orally every 12 hours on days 1-10. Gemcitabine 1000 milligrams per square meter (mg/m^2) administered intravenously (IV) over 30 minutes on days 3 and 10. Carboplatin dose Area Under Curve (AUC) 4 (mg-min/ml) administered IV over 30 minutes on day 3.
Maintenance: Cycles 7+ (28 day cycles)- 300 mg LY2228820 administered orally every 12 hours on days 1-14.

Experimental: Phase 1b 300 mg LY2228820 - Induction: Cycles 1-6 (21 day cycles)- 300 mg LY2228820 administered orally every 12 hours on days 1-10. Gemcitabine 1000 mg/m^2 administered IV over 30 minutes on days 3 and 10. Carboplatin dose AUC 4 administered IV over 30 minutes on day 3.
Maintenance: Cycles 7+ (28 day cycles)- 300 mg LY2228820 administered orally every 12 hours on days 1-14.

Experimental: Phase 2 dose LY2228820 - Induction: Cycles 1-6 (21 day cycles)- Recommended Phase 2 dose of LY2228820 administered orally every 12 hours on days 1-10. Gemcitabine 1000 mg/m^2 administered IV over 30 minutes on days 3 and 10. Carboplatin dose AUC 4 administered IV over 30 minutes on day 3.
Maintenance: Cycles 7+ (28 day cycles)- 300 mg LY2228820 administered orally every 12 hours on days 1-14.

Placebo Comparator: Phase 2 Placebo - Induction: Cycles 1-6 (21 day cycles)- Placebo administered orally every 12 hours on days 1-10. Gemcitabine 1000 mg/m^2 administered IV over 30 minutes on days 3 and 10. Carboplatin dose AUC 4 administered IV over 30 minutes on day 3.
Maintenance: Cycle 7+ (28 day cycles)- Placebo administered orally on days 1-14 to maintain blind.


Treatment: drugs: LY2228820
Administered Orally

Treatment: drugs: Carboplatin
Administered IV

Treatment: drugs: Placebo
Administered Orally

Treatment: drugs: Gemcitabine
Administered IV

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Phase 1b: Recommended Phase 2 Dose of LY2228820</outcome>
      <timepoint>Cycle 1 (21 Days)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Phase 2: Progression-Free Survival</outcome>
      <timepoint>Baseline to Date of Disease Progression or Death from any cause (estimated up to 3 years)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Phase 2: Percentage of Participants who Achieve Complete Response or Partial Response (Overall Response Rate)</outcome>
      <timepoint>Baseline to Disease Progression ( estimated up to 3 years)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival</outcome>
      <timepoint>Baseline to Date of Death from any cause (estimated up to 5 years)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics (PK): Area Under the Concentration Curve of LY2228820</outcome>
      <timepoint>Phase 1b Cycles 1-3 Days 1, 10 and 11 Predose up to 12 hours Postdose, Cycle 7 Day 3 Predose up to 8 hours Postdose; Phase 2 Cycles 1-2 Days 1, 3, 10 and 11 Predose up to 12 hours Postdose, Cycle 7 Day 3 Predose up to 8 hours Postdose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Phase 2: Change from Baseline in Functional Assessment of Cancer Therapy-Ovarian Cancer (FACT-O) score</outcome>
      <timepoint>Baseline, Study Completion (estimated up to 3 years)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Have been diagnosed with ovarian, fallopian tube, or primary peritoneal cancer

          -  Have been treated one time with a platinum-based chemotherapy and your disease has
             come back at least six months after you completed treatment

          -  Are able to swallow tablets

          -  Have given written informed consent prior to any study procedures

          -  Have adequate blood counts, hepatic and renal function

          -  Have performance status equal to or less than 2 on Eastern Cooperative Oncology Group
             (ECOG) scale

          -  Have negative pregnancy test, and if participant is of child bearing potential must
             use birth control while on study and for three months after stopping study drug</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Have been previously treated with Gemcitabine for ovarian, fallopian tube or primary
             peritoneal cancer

          -  Are currently enrolled or discontinued less than 14 days from another clinical trial

          -  Have a history of inflammatory bowel disease (Crohn's disease or ulcerative colitis)

          -  Have taken certain medications or had grapefruit juice within 7 days of initial dose
             of study drug, as levels of the study drug may be affected.

          -  Must not be pregnant or breastfeeding.

          -  Have malignancy or metastasis of the central nervous system

          -  Have borderline malignancy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1/Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>116</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/05/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Adelaide</hospital>
    <hospital>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Greenslopes</hospital>
    <hospital>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Nedlands</hospital>
    <hospital>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Parkville</hospital>
    <postcode>5000 - Adelaide</postcode>
    <postcode>4120 - Greenslopes</postcode>
    <postcode>6009 - Nedlands</postcode>
    <postcode>3053 - Parkville</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Essen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Greifswald</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mainz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>MÃ¼nchen</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Eli Lilly and Company</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>A study for women with ovarian cancer that has returned at least 6 months after
      platinum-based chemotherapy.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01663857</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9am-5pm Eastern time *UTC/GMT-5 hours, EST)</name>
      <address>Eli Lilly and Company</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>